ReviewGut and liver2026
Prevention and Management of Endoscopic Retrograde Cholangiopancreatography-Related Perforation: A Guideline-Based Narrative Review.
Review in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is important for the therapeutic management of pancreatobiliary diseases, but it carries a risk of perforation, an infrequent yet life-threatening adverse event. We summarize contemporary evidence on the prevention and management of ERCP-related perforation, aligning with current society guidelines (European Society of Gastrointestinal Endoscopy 2020, American Society for Gastrointestinal Endoscopy 2017, and Japan Gastroenterological Endoscopy Society 2018). We conducted a comprehensive narrative review by searching the PubMed, EMBASE, and Cochrane Library databases for articles published between January 2010 and October 2025. We prioritized current society guidelines, recent systematic reviews and meta-analyses, and landmark original studies, focusing on incidence, classification, risk factors, prevention strategies, and outcomes. Evidence was narratively synthesized to provide guideline-aligned recommendations. Perforation occurs in approximately 0.1% to 1.8% of ERCPs and is associated with substantial morbidity and mortality. The Stapfer system can be used to stratify injury severity and guide management. Most periampullary (Stapfer type II) and ductal (type III) injuries can be managed nonoperatively with endoscopic closure and/or diversion (e.g., fully covered self-expandable metal stents), whereas large, free-wall duodenal perforations (type I) often require early surgery. Early recognition, the use of CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.